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FOREWORD 
 
The Trent Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by Health Authority and 
Trust Chief Executives (HATCH) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterDEC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development, The Scottish Health Purchasing Information Centre 
(SHPIC) and The University of Birmingham Department of Public Health and Epidemiology. 
 
 
 
 
 
 
 
Professor R L Akehurst 
Chairman, Trent Working Group on Acute Purchasing 
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EXECUTIVE SUMMARY 
 
Carcinoma of the ovary is the commonest gynaecological malignancy and the fourth most 
common cause of cancer death in women. Around 70-80% of diagnosed patients are at 
stages III/IV with five year survival rates at less than 30% for those patients in advanced 
disease states. Based on data from the Office for National Statistics, it is estimated that 
ovarian cancer is responsible for between 4,500-5,000 deaths in the UK every year. 
 
In the last few years the drug paclitaxel has been introduced in treatment regimens, in 
combination with platinum drugs. In the US the combination paclitaxel/cisplatin is now 
considered to be the gold standard first-line therapy for advanced ovarian cancer. An 
internationally based inter-group trial, led by the European-Canadian Ovarian Cancer Inter-
group Trial (ECOCIT), was presented at the American Society of Clinical Oncology (ASCO) 
annual meeting in Los Angeles in May 1998. This trial follows the earlier GOG-111 trial, 
which originally indicated the potential overall survival and progression-free survival benefits 
of paclitaxel in first-line therapy. 
 
Including more than 1,000 patients with advanced disease, the two trials appear to have 
considered similar groups of patients, in terms of prognostic factors and general patient 
characteristics. The ECOCIT covered a slightly wider scope of severity with the inclusion of 
lower stage II disease. However, this represented only a small proportion of all recruited 
patients. Both trials randomised patients in a balanced way across the two treatment arms. 
 
Taken together, the trials report clear and significant clinical advantages for 
paclitaxel/cisplatin over cyclophosphamide/cisplatin based first-line therapy in terms of both 
progression-free survival (4-5 months/0.3-0.4 life years saved) and overall survival (10-14 
months/0.8-1.2 life years saved). These advantages appear to hold firm irrespective of 
patient prognostic factors and severity of disease. 
 
Clear, significant advantages in terms of clinical response were also noted in both trials, with 
that in the paclitaxel-based arms reported at 73-77% compared with a 60-66% clinical 
response in control arm patients.  
 
Using UK based estimates of treatment cost, the marginal cost per patient of 
paclitaxel/cisplatin therapy is £8,000. This represents a marginal cost of approximately 
£260,000 for a ‘typical’ district, assuming that 35% of patients would not be suitable for 
cisplatin-based treatment. 
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Comparing these marginal costs with the benefits predicted from the randomised trial 
evidence, it is estimated that the cost per life year saved lies in the range £7-11,000. This is 
based on a prediction of benefits comparing single-point median survival times. A similar 
comparison of progression-free survival indicates a cost per progression-free year of 
between £20-22,000. 
 
A sensitivity analysis was also conducted to explore the overall impact of potential reduction 
in hospitalisation costs due to shorter infusion times, but higher drug costs of dosage 
escalation, implied by the ECOCIT. This analysis indicates that the cost per life year range 
could be expected to be relatively little changed at around £7-12,000, given this form of 
higher dose regimen. 
 
The analysis also considered the potential range of the ratio of the trial median survival 
times of paclitaxel/cisplatin against cyclophosphamide/cisplatin. This confirmed the median 
survival time ratio as 1.4 (1.1 - 1.8 C.I. 95%) in favour of paclitaxel/cisplatin. Based on these 
figures the marginal survival benefit could fall anywhere between 0.3-1.6 life year gained.  
 
Since the publication of the Trent Institute Working Group on Acute Purchasing Guidance 
Note No. 97/05, in 1997, there have been eight separate cost-effectiveness studies 
published in peer reviewed journals. Although the studies are set within the context of 
different health care systems, and measure benefits in a number of different units, it is 
interesting to note that the cost-effectiveness ratios remain within a range of £5-15,000 per 
life year saved. These studies have been based on a mixture of modelled analysis and 
retrospective case-series reporting. 
 
The other major on-going trial which would also inform the first line paclitaxel debate is 
ICON 3, currently being conducted by the MRC within the UK. The trial aims to compare 
paclitaxel in combination with carboplatin against control arms of either single agent 
carboplatin or cyclophosphamide/cisplatin/doxorubicin (CAP). This trial has currently 
finished its recruitment phase, targeting around 2,000 patients, and is generally expected to 
begin producing interim results around the year 2000, but with full reporting some 2-3 years 
away. 
 
The key messages of the ECOCIT appear positive, confirming the clinical benefits achieved 
in the original GOG-111 trial. The results have been presented and debated in the context of 
local and national gynaecology group meetings, with positive clinical statements produced in 
the form of a recent clinical consensus document and a Joint Council for Clinical Oncology 
(JCCO) statement. The JCCO statement is widely expected to be endorsed by the NHS 
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Standing Medical Advisory Committee (SMAC). However, it is important to note also that the 
results of the ECOCIT have been communicated to date in abstract and presentation forms 
only, and have not been subject to any peer review process. 
 
Final publication and dissemination of the ECOCIT results are expected to re-enforce this 
clinical view. The eventual completion and publication of the ICON 3 results, in about two 
years’ time, will allow these conclusions to be revisited with regard to a carboplatin/ 
paclitaxel rather than a cisplatin/paclitaxel combination. 
 
It is concluded that the quality of newly available evidence further supports the use of 
paclitaxel, in combination with platinum compounds, in the first-line treatment of advanced 
ovarian cancer. 
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1.  INTRODUCTION 
 
Carcinoma of the ovary is the commonest gynaecological malignancy and the fourth most 
common cause of cancer death in women.
1
 
 
Within a ‘typical’ district there are expected to be around 100 newly reported cases of 
ovarian cancer every year. The reported annual incidence rate for the Trent region is around 
19 per 100,000 women.
2
 The Trent figures also indicate that approximately 50% of these 
cases are in women over the age of 65. With presentation of disease often delayed, due to 
the insidious nature of the illness, patients are often found to have advanced stages of 
disease at final diagnosis. International Federation of Obstetricians and Gynaecologists 
(FIGO) data suggest that around 70-80% of diagnosed patients are in stages  III/IV at initial 
presentation.
3
 Long-term prognosis is also generally poor, with five year survival rates for 
patients in advanced disease states quoted at less than 25-30%.
1
 Based on figures from the 
Office for National Statistics (ONS) it is estimated that ovarian cancer is responsible for 
between 4,500-5,000 deaths in the UK every year. 
 
To date, chemotherapy-based treatments for advanced ovarian cancer (AOC) have been 
based around platinum compounds, after analysis of early trial data suggested clear 
advantages over non-platinum-based therapy. The two key platinum drugs are cisplatin and 
carboplatin, which have been generally accepted to be of equal efficacy when used as 
single agent therapy.
4,5,6
 
 
More recently, platinum combination therapy has been promoted as a new alternative, the 
two most commonly used regimens being cyclophosphamide/cisplatin/doxorubicin (CAP) 
and cyclophosphamide/cisplatin (CP).
7,8
 Over the last few years the drug paclitaxel has also 
been introduced in treatment regimens, again in combination with platinum drugs. In the 
USA, paclitaxel/cisplatin (TP) is now considered the gold standard first-line therapy for AOC. 
This followed the publication in 1996 of a single randomised controlled trial (RCT) GOG-111, 
which compared TP to the then USA conventional approach based on CP therapy.
9
  
 
In 1997, the Trent Working Group on Acute Purchasing (Trent WGAP) produced a 
Guidance Note for Purchasers considering the evidence of effectiveness for paclitaxel in the 
first-line treatment of patients with AOC.
10
 The report was produced to support purchasing 
authorities in their decision-making processes as they came under increasing pressure to 
consider providing financial support for new paclitaxel-based therapies.  
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In identifying a suitable comparator, the Trent WGAP paper selected single agent 
carboplatin as the current UK standard therapy. The marginal cost of TP treatment was 
estimated to be around £8,500, representing the extra treatment costs above those already 
indicated for UK conventional treatment, based on single-agent carboplatin. As the control 
arm of the GOG-111 trial was not based around UK standard therapy, conservative clinical 
assumptions were taken to allow the original trial outcome data to be used directly as a 
proxy for carboplatin. On this basis the TP arm was predicted to provide a 1.1 life year gain 
(LYG) per patient.  Cost per LYG figures lay in the range £7-8,000, and these remained 
under £20,000 even after exploring wide confidence intervals to both costs and benefits 
through sensitivity analysis. The estimated marginal cost to an average health authority was 
estimated to be approximately £260,000, based on an uptake of therapy in around 65% of 
ovarian cancer patients. This represents those patients in advanced stage disease who are 
expected to have a functional status, measured as European Clinical Oncology Group 
(ECOG) performance status 0-2, sufficient to allow them to undergo TP based treatment.  
 
The Trent WGAP report concluded that, although based on only a single RCT, the evidence 
of clinical effectiveness was of a good quality, having been conducted by a well respected 
clinical group with adequate controls and a solid trial design. The cost-effectiveness ratios 
suggested by the available evidence indicated that TP therapy was comparable with existing 
supported therapies for ovarian cancer. 
 
As part of its recommendations, the Trent WGAP also suggested that the evidence should 
be reviewed further at some future date. This future review was deemed necessary 
because: 
 
 The clinical evidence was still based on a single trial only; 
 The control arm used represented a conventional therapy not commonly used in the UK 
(requiring some clinical assumptions in the calculation of benefits); 
 A large confirmative RCT trial was expected to complete within 18 months of publication; 
 Other ongoing RCTs were considering the use of paclitaxel in other combinations (i.e. 
with carboplatin, at different infusion rates etc.). 
 
The European-Canadian Ovarian Cancer Inter-group Trial (ECOCIT) was presented at the 
American Society of Clinical Oncology (ASCO) annual meeting in Los Angeles in May 1998. 
This trial represents an internationally-based study and was conducted through the 
European Organisation for Research and Treatment of Cancer (EORTC), the Canadian 
National Cancer Institute (NCIC), the Scottish Gynaecological Study Group (GCSG) and 
Scandinavian Gynaecological Cancer Study Group (NOCOVA). The rationale behind the 
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trial design was to provide an opportunity to provide independent consideration to the results 
of the original Gynecologic Oncology Group (GOG) trial. Data from the ECOCIT have been 
released in abstract form, with a full publication in a peer-reviewed journal expected later.
11
 
Moreover, the EOCIT results have been subject to critical consideration through the 
development of a recent statement by the Joint Council for Clinical Oncology (JCCO) and 
the publication of a clinical consensus document, as well as the ASCO process itself.   
 
The recently published clinical consensus document cites the results of both the ECOCIT 
and the earlier GOG-111 trial and strongly advocates the introduction of TP as a 
recommended first-line therapy for AOC.
12
 The consensus document also points towards 
the outcome advantage of managing patients though specialist multidisciplinary teams, an 
issue further recognised and supported by the Royal College of Obstetricians and 
Gynaecologists and the British Gynaecological Cancer Society.
13
 The consensus panel 
covered a wide range of UK clinicians and was co-ordinated under the guidance of Dr Martin 
Gore of The Royal Marsden Hospital. 
 
The  published statement from the JCCO recommends that a combination of paclitaxel and 
a platinum compound is the most effective first-line therapy for ovarian cancer patients, and 
that the majority of patients should be considered for this treatment. The statement also 
calls for regular audits of treatment for ovarian cancer.
14
 
 
Wider commissioning guidelines, covering all gynaecological cancers, are planned for 
release in early 1999. These guidelines, forming part of the implementation process of the 
Calman/Hine recommendations, are intended to provide guidance on the organisation and 
management of services for all gynaecological cancers including AOC.
15
 However, as a 
result of the recent movement in the AOC evidence-base, and with the expected increase in 
pressure on health authorities to provide new treatments for AOC, the Department of Health 
(DoH) has now made a direct request for a follow-up evidence review document. The 
purpose of this supplementary document to the Trent WGAP report is to support the DoH in 
its dissemination of evidence, through the Standing Medical Advisory Committee (SMAC), to 
health authorities throughout the UK, prior to the release of these wider gynaecological 
guidelines. 
 
This supplementary document considers the latest evidence of clinical effectiveness and 
should be read alongside the original Trent WGAP document.
10
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2. USE OF PACLITAXEL IN THE FIRST LINE TREATMENT OF OVARIAN                 
CANCER: SUMMARY OF EVIDENCE OF EFFECTIVENESS 
 
To date, the published evidence of clinical effectiveness for the use of TP as a first-line 
treatment in AOC has come exclusively from a single RCT conducted by the Gynecologic  
Oncology Group (GOG), the GOG-111 trial.
9
 This trial was considered in some detail within 
the original Trent WGAP report and formed the basis of the economic analysis presented. 
The trial was well supported and welcomed by clinicians, although there was a general view 
that confirmatory data would add further weight to the evidence-base.
16
 
 
The GOG-111 trial was published in the New England Journal of Medicine in 1996 and was 
the first large randomised trial to consider the role of paclitaxel as a first line therapy. The 
trial was based on 400 women with advanced staged disease and showed clear advantages 
in terms of both progression-free survival and overall survival, although only the latter was a 
primary end-point of the trial. The following tables summarise the clinical benefits suggested 
by the trial. A fuller consideration of the trial design and outcomes can be found in the Trent 
WGAP report.
10 
 
GOG-111 Trial Results 
 
Table 1 GOG-111 Median Survival 
Regime Median Survival  95% CI Interval 
Paclitaxel/Cisplatin (TP) 38 months 32 - 44 months 
Cyclophosphamide/Cisplatin (CP) 24 months 21 - 30 months 
Marginal Benefit 14 months(p < 0.001)  
 
Table 2  GOG-111 Median Progression-free Survival 
Regime Median Progression-free 
Survival  
95% CI Interval 
Paclitaxel/Cisplatin (TP) 18 months 16 - 21 months 
Cyclophosphamide/Cisplatin (CP) 13 months 11 - 15 months 
Marginal Benefit 5 months(p < 0.001)  
 
The differences in both progression-free and survival benefits were both significant  
(p < 0.001) and favoured the TP group over the CP group. 
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More recently, a second RCT has reached completion, which again considers the role of TP 
in the first-line treatment of AOC. This multicentre international trial, co-ordinated by the 
ECOCIT, reported at the May 1998 meeting of the ASCO.
11
 The results from the trial are 
expected to be  published in full. 
 
The overall rationale for the ECOCIT was to provide an independent body of evidence either 
to  confirm or refute the results of the GOG-111 trial. This confirmatory trial is generally seen 
as providing further support to the results of the GOG-111 trial, and the general clinical 
opinion within the UK is that it will prove to be the catalyst for a world-wide movement 
towards TP being introduced as a recommended first-line treatment.
12
 
 
Currently, the only publicly available evidence upon which any judgements of the ECOCIT 
can be  made are: 
 abstract published for the ASCO 1997 meeting;
17
 
 copies of interim results slides presented at ASCO 1997;
18
 
 abstract published for the ASCO 1998 meeting;
11
 
 copies of final results slides presented at ASCO 1998;
19
 
 
The remainder of this chapter provides a summary of the abstract published ECOCIT data, 
making direct comparisons to the GOG-111 trial, where appropriate, and drawing together 
an up-dated picture of the current state of the evidence for the clinical effectiveness of TP. 
 
2.1  ECOCIT Design 
 
2.1.1  Trial End-points 
The primary end-point of the trial was progression-free survival, with secondary end-points 
targeted at: overall survival; clinical response rate; and quality of life. Cost-effectiveness was 
also cited as a secondary outcome, although no data are provided. The key reason for this 
secondary consideration of survival was the fact that the trial allowed cross-over to paclitaxel 
for control-group patients with disease progression. The expected effects of approved cross-
over are a reduction in the likelihood of any significant survival difference being detected.  
This contrasts with the GOG-111 trial, which was primarily focused on overall survival as a 
trial end-point; cross-over was far more limited in this case as paclitaxel was not generally 
available. This fact is an important one, as the GOG-111 survival data are likely to be unique 
in the fact that they are influenced by limited patient cross-overs. 
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2.1.2  Treatment Arms 
The ECOCIT was conducted on 680 ovarian cancer patients, who were randomised in 
roughly equal numbers over two treatment groups using CP as a control arm, as in the 
GOG-111 trial. This represents a much larger group of patients than covered by the GOG-
111 trial, which was based on 410 similarly randomised patients. 
 
The following summarises the specific treatment regimens used in the two treatment arms. 
 
Table 3  ECOCIT Treatment Arms 
Arm A (Control Arm) Arm B (Treatment Arm) 
 Cyclophosphamide 750 mg/m
2
 
 Cisplatin 75 mg/m
2
  
 Repeated every three weeks 
 Up to nine cycles 
 IDS allowed 
 Number of patients = 330 
 Paclitaxel 175-200 mg/m
2
 
 3 hour infusion 
 Cisplatin 75 mg/m
2
 
 Repeated every three weeks  
 Up to nine cycles 
 IDS allowed 
 Number of patients = 338 
     IDS = Interval Debulking Surgery                  Source : Proc ASCO Vol 17 1998 
  
 
As with the GOG-111 trial, the control arm used is based on CP. This is not typical of the UK 
where conventional treatment is generally based on either single agent carboplatin or CAP.
7  
 
Importantly, the dosage of cisplatin in the control arm represents optimum treatment as, 
beyond this level, renal toxicity would cause significant side-effects. 
 
2.1.3  Patient Characteristics 
The severity of disease was much broader in the ECOCIT, with optimally debulked patients 
at stage II accepted. The earlier GOG-111 trial had been more restrictive in terms of patient 
disease severity, limiting entry to those with surgically sub-optimally debulked stage III/IV 
disease. However, patient characteristics show that in both trial arms roughly 93-94% of 
patients were at either stage III or stage IV of advanced disease. The World Health 
Organisation (WHO) performance status was also similar across both groups, with 
comparable age ranges and overall median ages of 58 in both arms. This compares with 
median ages of 59-60 in the GOG-111 trial, and similar ranges from around 20-80. The 
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distribution of cell-type between the patient groups was virtually identical in the two ECOCIT 
arms, and was also very similar to those reported in the GOG-111 trial. 
 
Optimal residual disease was defined as none, microscopic or <1cm maximum dimension. 
 
Interval debulking surgery (IDS) was permitted in ECOCIT with 8-9% of patients in both 
arms operated on after the first three courses of chemotherapy. Second-look surgery was 
optional in the trial and was conducted in 17% and 21% of the CP and TP arms respectively. 
 
Table 4 ECOCIT Patient Characteristics 
 Control Arm: CP Treatment Arm: TP 
Number 330 338 
Median Age & Range 58 (22-85) 58 (23-79) 
 Number % Number % 
WHO Performance Status     
0  168 51%  157  46% 
1  119 36%  135  40% 
2  39 12%  40  12% 
3 or missing  4 1%  6  2% 
FIGO
a
 Stage     
II  24  7%  21  6% 
III  235  71%  253  75% 
IV  71  22%  64  19% 
Tumour Grade     
1  26  8%  27  8% 
2  82  25%  91  27% 
3  190  58%  193  57% 
Missing or Not Applicable  32  10%  27  8% 
Cell Type     
Serous adenocarcinoma  208  63%  234  69% 
Endometrioid adenocarcinoma  44  13%  31  9% 
Mucinous adenocarcinoma  17  5%  12  4% 
Clear-cell adenocarcinoma  17  5%  15  4% 
Other  44  14%  46  14% 
 Source : Proc ASCO Vol 17 1997 
                                               
a
 FIGO - International Federation of Obstetricians and Gynaecologists 
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The following shows the rough split of patients over the treatment arms based on levels of 
debulking: 
 
Table 5 Residual Disease Presence in the ECOCIT  
 Control Arm : CP Treatment Arm : TP 
Optimal Residual Disease  111  33%  138  38% 
Suboptimal Residual Disease  216  65%  209  62% 
Presence Of Measurable Disease  151  46%  149  44% 
 Source : Proc ASCO Vol 17 1998 
 
2.1.4  Summary of Trial Characteristics 
The key differences between the ECOCIT and the GOG-111 trials are summarised as: 
1. the ECOCIT allowed entry for optimally debulked patients (i.e. less severe prognosis 
group); 
2. TP treatment was based on a 3-hour infusion and a slightly higher dosage of paclitaxel; 
3. the primary end-point was progression-free survival; 
4. paclitaxel was available as salvage for control arm patients with disease progression. 
 
The following table compares and summarises further the designs of the two main trials. 
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Table 6  Comparison of the GOG-111 and ECOCIT Randomised Trials 
Design Aspect ECOCIT GOG-111 
Patient Groupings Sub-optimal  & Optimal Residual 
Disease 
FIGO IIB IIC III IV 
Sub-optimal Residual Disease 
 
FIGO III IV 
Cisplatin Dosage 75mg/m
2
 75mg/m
2
 
Paclitaxel Dosage 175-200 mg/m
2
 135 mg/m
2
 
Paclitaxel Infusion 3 hours 24 hours 
Number of Cycles Up to a maximum of 9  
(repeated every 3 weeks) 
6 
(repeated every 3 weeks) 
Interval Debulking Surgery Optional No 
Second Look Surgery Optional Yes 
Patient Numbers 680 randomised 
668 patients eligible 
410 randomised 
386 patients eligible 
Median Follow-up 30 months 37 months 
Recruitment/Study Period 4/1994 to 8/1995 (18 months) Not known 
 
The two trials appear to have considered similar groups of patients in terms of prognostic 
factors and general patient characteristics. The ECOCIT covered a much wider scope of 
disease severity with the inclusion of lower stage II disease and well debulked stage III 
disease. This represented around a third of all recruited patients. The trial protocol provides 
some detail on method of patient randomisation and cites the minimisation technique 
detailed by Pocock et al.
20
 The reported patient characteristics appear to suggest an 
acceptable randomisation of patients between the two treatment arms. 
 
2.2  ECOCIT End-point Data 
 
The only published outcome data from the ECOCIT results come from abstracts published 
and presented at the ASCO 1997 and 1998 meetings. The first abstract and presentation 
form an interim analysis and, together, claimed a higher clinical response rate (77% 
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compared to 66%) for the TP arm over the CP arm. This advantage was statistically 
significant with a p-value of 0.02. The presentation also referred to a longer progression-free 
survival (16 months compared to 12 months) again in favour of the TP arm.  Importantly, 
this difference in progression-free survival was noted in patients with either sub-optimal or 
optimal disease. 
 
Table 7 ECOCIT Abstract - Primary Outcome Progression-free Data 
 Source : Proc ASCO Vol 17 1998 
 CP TP p-value 
Median Progression-free Survival (months) 12 16 p=0.0001 
 
 
Presenting an up-dated analysis, the 1998 abstract reports on a median trial follow-up 
period of 28 months. This appears to confirm both the differences in clinical response rate 
and progression-free survival as presented at the 1997 ASCO meeting. The abstract goes 
further in presenting the following table, highlighting statistically significant differences in the 
secondary trial end-point of overall survival.  
 
 Table 8 ECOCIT Abstract - Secondary Outcome Survival Data 
 CP TP 
Events/Patients 168/337 (49.9%) 131/342 (38.3%) 
Median Overall Survival 
(months) 
25 35 
Logrank p-value p<0.001 
 Source : Proc ASCO Vol 17 1998 
 
Further trial details and outcomes, outside the scope of the original published abstract data, 
have been presented at the ASCO 1998 meeting. These data help to provide a more in-
depth view of the significance of clinical outcomes and also begin to allow for the effects of 
case-mix to be taken into consideration. Therefore, the remainder of the review of trial 
outcome data has been based on the content of the original presentation slides, which 
remains unpublished in any peer reviewed journal. These data have also been reviewed by 
the UK clinical consensus group and the JCCO.
14
 
 
In terms of the general principles adopted by the trial group, the outcome data have been 
analysed under the following conditions: 
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 Outcome analysis from the trial is based on an intention-to-treat basis;  
 Kaplan-Meier techniques have been used to analyse the outcome data using 2-sided 
logrank tests to identify the level of statistical significance;  
 A Cox-regression analysis has been conducted to adjust outcomes for a range of 
prognostic factors; 
 The presented data are based on a 30 month median patient follow-up. 
   
2.2.1  Progression-free Survival 
The primary end-point of the trial was progression-free survival. The following table presents 
the results both with and without adjustments for prognostic factors. The median 
progression-free survival was 16.6 months in the TP arm, compared with 12 months in the 
CP control arm. This difference of over four months was statistically significant (p<0.001) 
and remained so after prognostic adjustment. The confidence intervals remain somewhat 
tight around the relative risks and do not approach unity. The risk ratio has been calculated 
using Kaplan- Meier survival curve techniques over the whole of the trial period. 
 
Table 9 Progression-free Survival Unadjusted/Adjusted for Prognostic Factors 
 Risk Ratio 95% C.I. p-value 
Unadjusted  0.68 0.57 to 0.81 <0.001 
Adjusted for Prognostic Factors  0.66 0.54 to 0.79 <0.003 
 Source : Proc ASCO Vol 17 1998 
 median follow-up 30 mths 
 
2.2.2  Overall Survival 
Although only intended as a secondary outcome, significant differences were also found in 
overall survival (p < 0.001). Importantly, this is despite the allowed cross-over to Paclitaxel 
for control arm patients at onset of disease progression, coupled with the intention-to-treat 
basis of the analysis.  Again, adjustment for prognostic factors did not alter this difference 
greatly. 
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Table 10  Survival Unadjusted/Adjusted for Prognostic Factors 
 Risk Ratio 95% C.I. p-value 
Unadjusted 0.70 0.56 to 0.87 <0.001 
Adjusted for Prognostic Factors 0.71 0.57 to 0.89 <0.003 
 Source : Proc ASCO Vol 17 1998 
 median follow-up 30 mths 
 
Taken together, the data presented at the ASCO meeting appear to confirm that both the 
survival and progression-free advantages of TP remain significant in both sub-optimal and 
optimal residual disease. This is an interesting result as it appears to suggest that, even in 
patients with less advanced disease, an advantage is clear. 
 
The fact that survival data remain significantly different, despite the allowance for wide 
cross-over on disease progression,  would appear to suggest the advantage of TP as a first-
line therapy is clear; that is, aside from its use as second and third line salvage therapy. In 
general, it would be expected that any large scale patient cross-over to salvage therapy 
within trial would reduce the difference between the overall survival results. However, it is 
also true that, where patients  are in relapse, the advantage of any salvage therapy would 
be expected to be greatly reduced.  
 
2.2.3  Pooled Survival Data 
The recently issued consensus document suggests the following pooled data for the overall 
relative risk of survival.
12  
The relative risk is assumed to be calculated from the Kaplan-
Meier data plots over the period of follow-up for both trials.  
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Table 11 Consensus - Pooled Survival Data 
Trial n Median 
Survival 
(months) 
Relative Risk C.I. 95% p-value 
  CP TP    
GOG-111 386 24 38  0.6  (0.5-0.8)  <0.001 
ECOCIT 686 25 35  0.71 (0.57-0.87)  0.003 
Pooled 1,054 - -  0.66 (0.56-0.77) <0.000001 
 Source : Consensus Document 
 
The approach is based on a simple meta-analysis of the two trials using the log 
transformations of relative risks, with weightings based on the inverse of the variances. A 
similar pooling analysis has been conducted by the Trent WGAP authors using the same 
overall relative risk data. It follows the general variance with confidence intervals 
methodology as supported and suggested by Petitti et al. 1994.
21
  This approach assumes a 
fixed-effects basis to the meta-analysis and enables the pooled risk ratio to be calculated, 
along with variance and confidence intervals, using only published trial estimates of relative 
risk. The validity of the test relies on the trial data passing a test of heterogeneity. The 
results of the Trent WGAP analysis are virtually identical to those presented in the 
consensus document. 
 
Table 12 Trent - Pooled Survival Data 
Pooled Trial Data Relative 
Risk 
C.I. 95% p-value 
Trent Approximation 0.64 (0.56-0.77) <0.000001 
Consensus Approximation 0.64 (0.56-0.74) <0.000001 
 
This small meta-analysis of the two trials confirms a real clinical difference in terms of 
survival, with a narrowing of the confidence intervals when pooling the trial data. 
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2.2.4  Confidence Interval on Median Survival Times 
It is possible, from the data presented in abstract form, to calculate a confidence interval 
around the ratio of median survival times. The purpose of this is to explore the range within 
which the difference in the medians could realistically be expected to lie. 
 
The method for calculating the confidence interval of the ratio is covered by Altman and is 
based on an approximation of variance based on the number of observed events.
22
  An 
assumption of exponentially distributed survival times is required and, although easily 
checked, the raw data are required. Based on this approach, and assuming that exponential 
survival times hold, the following results are suggested. 
 
Table 13 Confidence Interval of Median Survival Difference 
Median 
Survival 
(months) 
Difference 
in Median 
Survival 
Ratio of 
Median 
Survival 
C.I. 95% 
(months) 
CP TP (months) (TP/CP) Lower Upper 
25 35 10 1.40 1.11 1.76 
 
The 95% confidence interval does not cross unity, again providing support to the strength of 
survival benefit towards TP. This calculation is obviously closely related to the risk ratio 
calculations presented at the ASCO meeting. 
 
This information is also very useful in implying the range of confidence that should be 
adopted in using the difference in median survival outcome in the calculation of cost-
effectiveness ratios. This issue is expanded in Chapter 3. 
 
2.2.5  Prognosis Factors 
The following table highlights the range of prognostic factors used in the Cox-regression 
analysis. These factors cover issues of severity of disease and patient morbidity and again 
are similar to the patient classification data used in the analysis of the GOG-111 data. 
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Table 14  Prognostic Factors 
Prognostic Factor Range 
Age <=58 years, >58 years 
WHO performance status 0,1,2,3 
FIGO stage II,III,IV 
Histology serous, other 
Grade 1,2,3,UK 
Measurability Yes, No, NED 
Residual Disease No, <=1cm, >1cm 
 Source : Proc ASCO Vol 17 1998 
 
 
2.2.6   Clinical Response 
The ECOCIT reports rates of clinical response (CR) to treatment in those with measurable 
disease after debulking surgery. These rates show a significant difference in the level of CR 
(p=0.02); however, the strict definitions of CR are not provided in the presentation slides. 
 
 
Table 15 ECOCIT Clinical Response Rates 
Treatment Arm Complete 
Response 
Partial 
Response 
Clinical 
Response 
Surgical 
Response 
TP 50% 27% 77% 47% 
CP 36% 30% 66% 24% 
Difference 14% -3% 11% (p=0.02) 23% 
 Source : Proc ASCO Vol 17 1997 
 
This level of difference is also reflected in the results of the original GOG-111 trial where the 
levels of response were observed in 216 patients with measurable disease after debulking 
surgery. 
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Table 16 GOG-111 Clinical Response Rates 
Treatment Arm Complete Response Partial Response Clinical Response 
TP  51% 22% 73% 
CP 31% 29% 60% 
Difference 20% (p=0.01) -7% 13% 
 Source : Proc ASCO Vol 17 1998 
 
2.2.7  Patient Drop-outs 
The GOG-111 trial reports a total 160 out of 184 patients successfully completing the TP 
regimen, representing an 87% completion rate. This compares with 158 of 202 patients, or 
78%, completing the conventional CP treatment. When considering those drop-outs for 
reasons other than clinical disease progression or death, the apparent difference between 
treatment arms reduces with only an 8% drop-out rate in the TP arm compared to 10% in 
the CP arm.  
 
The ASCO presented data do not allow us to make any real judgement about the levels of 
patient drop-out during the trial. If accessible, this could be compared to the results of the 
GOG-111 trial, which appear to show no real difference in terms of drop-outs related to the 
levels of toxicity. 
 
What is provided is a breakdown of reasons for ineligibility following the initial randomisation 
or trial entry of patients. In total, 12 patients were excluded from the ECOCIT due to: wrong 
histology(6); second malignancy(4); wrong stage(1); and poor medical condition(1). This 
compares with 24 patients ruled out of the GOG-111 trial due to: inappropriate staging(3); 
histology(13); cell type(3); history of cancer(4); and wrong surgery type(1). 
 
2.2.8  Observed Toxicity 
In a review of the toxicity events noted during the ECOCIT, the following areas were 
identified as being associated with significantly higher rates in the TP arm: 
 alopecia;  severe arthralgia; 
 hypersensitivity;  myalgia. 
 neurotoxicity;  
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It was also noted that grade 3 and 4 nausea and vomiting was less common in the TP arm. 
Both arms were noted to have comparable grade 3 and 4 neuropenia. 
 
The GOG 111 trial reported significant differences in toxicity with TP being associated with 
higher rates in the following areas,  p<0.05: 
 alopecia;  febrile neutropenia; 
 neutropenia;  peripheral neurotoxicity. 
 
The interim report comments on the comparatively higher rates of severe neurotoxicity in the 
ECOCIT compared to the GOG-111 trial. This is speculated to be due to the higher doses 
and shorter infusion times used. Without further data behind the rates of toxic events, it is 
difficult to draw any further conclusions from the trial comparisons. These data would be 
particularly useful in establishing patient quality of life estimates.  
 
2.2.9  Patient Cross-Over 
As previously stated, patients in the control arm were allowed to switch treatment to salvage 
TP therapy on the onset of disease progression. The final analysis reports that 52% of 
patients from the control arm crossed over to a paclitaxel-based therapy at some point in the 
trial.   
 
Following the 6th cycle of therapy, patients who remained disease-free were allowed to 
move to different combinations of their existing therapy. However, control arm patients were 
not allowed to receive paclitaxel. 
 
The following table is taken from the interim analysis in 1997 and shows the levels of dose 
escalation of paclitaxel-treated patients. The table also highlights the number of patients 
who had their cisplatin component substituted by carboplatin. This change of platinum 
component was only allowed after six cycles of therapy and only in cases where patients 
were experiencing renal- neuro- or ototoxicity related to the cisplatin. 
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Table 17 ECOCIT Patient Switching 
 Control Arm : CP Treatment Arm : TP 
No. of patients where carboplatin 
was substituted for cisplatin                     
(after 6 courses of therapy) 
30 9% 43 12% 
No. of patients increasing their 
paclitaxel dosage 
- - 233 70% 
 
It is interesting to note that a large proportion of the paclitaxel-treated patients experienced 
dose escalation, i.e. 200 mg/m
2
. The trial protocol allowed TP treated patients to move to 
this higher dosage of paclitaxel if they experienced no toxic effects after the first cycle. If 
problems were then experienced, patients returned to the original dosage for the remaining 
cycles. 
 
Cisplatin dosage was reduced by 20% of the original dosage if febrile neutropenia was 
evident after the first or subsequent treatment cycles. 
 
2.2.10 Quality of Life Indicators 
A limited amount of quality of life analysis has been conducted by the trial group. This has 
been based on patient views taken via questionnaire. Changes in these patient views were 
compared to  210 baseline patients. This questionnaire covered areas such as: 
 
 fatigue;   insomnia;  
 constipation;  cognitive functioning; 
 appetite loss;  global Quality of Life. 
 pain;  
 
The exact tools used to measure these quality of life (QoL) score changes are not detailed. 
Early reports suggest that the QoL in the two treatment arms is roughly comparable, with 
some significant differences in favour of both CP and TP, but only at specific time-points. 
There are plans, however, for further longitudinal analysis. This is likely to appear in greater 
detail in the final published paper. 
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2.3  Remaining Evidence of Effectiveness 
 
Besides the GOG-111 trial and the ECOCIT, there are two further trials which have been 
reported in abstract form. These trials help to add to the body of knowledge regarding the 
use of paclitaxel. 
 
du Bois  
The du Bois
23
 trial compared TP with a treatment of carboplatin/paclitaxel in a group of 798 
patients. As in the GOG-111 trial, cisplatin was used at a dosage of 75mg/m
2
 and the 
paclitaxel was infused over a three hour period. However, the dosage of paclitaxel was 
increased to 185 mg/m
2
. This set of interim results indicates a median progression-free 
survival of 16.6 months for the patient group as a whole, with no significant difference 
between the treatment arms. A 74% CR rate is also reported, again similar to the findings of 
the GOG-111 trial and the ECOCIT. Apart from alopecia, non-haematological toxicity 
occurred more frequently in the cisplatin arm. QoL measurement pointed towards a much 
inferior patient experience (p<0.008) in the cisplatin arm.  
 
GOG-132 
The GOG-132 trial
24
, conducted in over 600 patients, compared three treatment regimens: 
 Combination therapy - paclitaxel infused over a 24 hour period at a dosage of 135 
mg/m
2
,  cisplatin was set at a dosage of 75mg/m
2
; 
 Single agent therapy -  cisplatin dosage was higher at 100 mg/m
2
; 
 Single agent therapy - paclitaxel was infused over a 24 hour period at a dosage of 200 
mg/m
2
. 
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Table 18 GOG-132 Trial Results 
GOG132 Number 
of 
Patients 
Median 
Progression-
free Survival 
(months) 
Median 
Overall 
Survival 
(months) 
Paclitaxel/cisplatin (TP) 201 14 26 
Cisplatin 200 16 30 
Paclitaxel 213 11 26 
 
The results of this trial appear to contradict the earlier findings of the GOG-111 trial and the 
ECOCIT. The results point towards no significant differences between high dose 
(100mg/m
2
) cisplatin and the TP treatments. Importantly, paclitaxel, as a single agent, was 
proven to be significantly inferior in terms of both outcome measures.  
 
However, the study design of this trial has been widely debated, particularly in respect of the 
amount of patient cross-over permitted in the early stages of treatment. A proportion of 
patients treated with single agent cisplatin did cross-over to the TP arm without showing any 
sign of clinical progression.  The precise numbers of such patients remain unknown. This 
coincided with the abstract release of early positive results from the GOG-111 trial and it is 
felt that this could explain the possible shift in clinical practice. The majority clinical opinion 
appears to be that this trial remains very difficult to interpret as a result of this early, 
unquantified cross-over issue.
25
   
 
2.4  Summary of Clinical Evidence 
 
There now exist four independent RCTs which have considered the role of TP as a first-line 
treatment for AOC. All trials have been based in relatively large populations, (of at least 380 
patients) and represent a broad mix of patients with advanced disease in stages IIB, IIC, III 
and IV. Three of these trials appear to suggest that paclitaxel, in combination with cisplatin, 
should be expected to provide definite patient benefits, in terms of both progression-free 
survival and overall survival. One trial suggests that no real difference exists, when using 
high dose (100mg/m
2
) single agent platinum therapy.  However, its study design has been 
questioned.  
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The two major trials, GOG-111 and ECOCIT, are similar in their comparison to a standard 
therapy based on CP. Although both trials use conventional therapies not commonly used in 
the UK, it is possible to make methodologically sound clinical links with the UK standard of 
single agent carboplatin.  Previous trial data suggest that carboplatin should be expected to 
have very similar efficacy and outcomes to either of the control arms used.
8
 Therefore, 
equating the control arm benefits with those expected from carboplatin should represent a 
fair estimate of paclitaxel’s benefits. 
 
Both trials report clinical advantages for TP over CP based first-line therapy in terms of both 
progression-free survival (4-5 months) and overall survival (10-14 months). These 
advantages appear to hold firm irrespective of patient prognostic factors and severity of 
disease. The trial data and analysis do not allow any patient sub-groups to be explored to 
identify those who would benefit more or less from treatment. 
 
The survival differences of the ECOCIT were achieved, despite a high rate of patient cross-
over to TP on eventual disease progression. This fact has been claimed by some as support 
to the real first-line advantage of TP, following a logical argument that, if TP were as 
effective in second-line therapy, we would have expected to see much closer survival 
results. 
 
The ECOCIT results also point towards the efficacy of a shorter time-period of infusion for 
paclitaxel (three hours). This could have potential impact in terms of movement towards 
reducing the amount of overnight admissions, representing a potential cost saving. It is not 
possible, from abstract results alone, to identify the actual hospital resource usage of the TP 
arm. Within our cost calculations we assumed that each course would require a single night 
in-patient stay, although this could be arguably less depending on treatment duration. 
 
Both trials clearly demonstrate that there is a range of toxic effects which are associated 
with TP; however, these do not appear to be detrimental to the overall clinical advantages of 
the therapy. The shorter infusion time will raise the level of some toxic effects; however, 
other neurological effects are reduced. It is difficult to make any further conclusions without 
access to more detailed data. 
 
The other major on-going trial, which will also inform the first line paclitaxel debate, is ICON  
3, currently being conducted by the MRC within the UK and Italy.
7
 This trial will, for the first 
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time, provide data on the first line use of paclitaxel-based treatment strictly within a UK 
setting. The trial aims to compare paclitaxel in combination with carboplatin against control 
arms of either single agent carboplatin or CAP. This trial has currently finished its 
recruitment phase, targeting around 2,000 patients, and is generally expected to start 
producing interim results around the year 2000, with full reporting some 2-3 years away. 
 
Currently, internationally-based trials are looking at direct comparisons of TP versus 
paclitaxel-carboplatin therapy with the expectation that a carboplatin-based combination 
would be less toxic.
23, 26,27
  Whilst these trials are still some way off any full publication of 
survival outcomes, they do begin to suggest equal efficacy between the treatments in terms 
of both progression-free survival and CR rates. Interestingly, one trial reports progression-
free survival rates of 16 months for both arms, which are again very close to those identified 
in both the GOG-111 trial and ECOCIT. They also suggest lower rates of neurotoxicity in the 
paclitaxel/carboplatin arm. In measures of patient QoL, using the ECOCIT Quality of Life 
Questionnaire, a significant advantage was found for the carboplatin-based arm (p=0.008).  
However, no firm conclusions can be drawn effectively before further publication. 
 
The ECOCIT and GOG-111 trial appear to provide confirmation of paclitaxel’s potential 
clinical benefits in the first-line treatment of AOC. Although not presented as yet in a peer-
reviewed journal, it is likely that full publication of the ECOCIT will consolidate the data 
already presented to the ASCO. Given the comparative nature of cisplatin and carboplatin, it 
is also likely that ongoing explorations of paclitaxel in combination with carboplatin will 
produce similar trial results. The advantages of carboplatin may become more apparent with 
its reduced toxicity.  
 
Whilst it is important to stress that the ECOCIT has only been published in abstract form, 
following presentation at the ASCO 1997 and 1998 meetings, this process will have involved 
some degree of peer review. A full published paper is anticipated and this should provide 
further data and more details of the actual methodology used. The paper will also allow 
considerations of this evidence to be discussed in the public domain. The JCCO statement 
and clinical consensus document also provide a considered opinion of the trial outcomes.
14
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3.  COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
3.1  Revised Cost Analysis 
 
In the original primary cost-analysis, the published median survival and progression-free 
statistics from the GOG-111 trial were used to bring together a picture of cost-effectiveness. 
It was necessary, in the absence of any published trial cost data, to base the predicted costs 
of TP and carboplatin therapy using UK regional costings. The range of costs used included 
drugs, the management of adverse effects and hospitalisation. More details of the costings 
used can be found in the Trent WGAP report.
10 
 
Table 19 Cost of Treatment 
Regime Cost Per Patient Average District 
Cost 
Trent Regional 
Cost 
Paclitaxel/Cisplatin (TP) £10,427 £321,932 £3,108,574 
Carboplatin   £2,059   £63,564    £613,774 
Marginal Cost Difference   £8,368 £258,368 £2,494,800 
 
The extra or marginal cost per patient between the two treatments is estimated at £8,368.  
 
The following table presents the original cost per life year gained (LYG) analysis and 
repeats the calculations using ECOCIT outcome measures. In building this cost-
effectiveness analysis we have used treatment costs based on our original estimates. 
However, we then consider the potential impact of any reduction in hospitalisation (i.e. a 
move to out-patient treatment) and also a possible increase in drug dosage (175 mg) as 
suggested by the ECOCIT. 
 
The economic analysis of TP varies very little irrespective of which trial results are used. 
The ECOCIT survival benefits show slightly less difference from those suggested by the 
GOG-111 trial, despite the fact that patients with a wider scope of disease severity were 
recruited into the study. However, they remain clearly significant. 
 
  27 
Table 20 Revised Cost-effectiveness Analysis 
 
Overall Survival Progression-Free Survival 
  
GOG-111 ECOCIT GOG-111 ECOCIT 
(A) Marginal LYG per 
person 
1.17 
(14 months) 
0.83 
(10 months) 
0.42 
(5 months) 
0.38 
(4 months) 
(B) Marginal Treatment 
Cost per person 
£8,368  £8,368 £8,368  £8,368 
(B/A) Cost per LYG £7,173 £10,081 £20,084 £22,021 
 
3.2  Sensitivity Analysis 
 
The original sensitivity analysis indicated that the cost-effectiveness argument was robust to 
changes in drug costs, hospitalisation costs and clinical benefits. In the case of the ECOCIT 
data, the reduction to a three hour infusion of TP would reduce the need for any in-patient 
stay to a single overnight stop. This would have the effect of reducing the potential marginal 
cost of the new treatment. If the three hour infusion reduced the need for in-patient stay 
from two days to one day per course, then the total cost of treatment for TP would fall by 
around £1,200. This would in turn reduce the marginal cost to around £7,000. On this basis, 
the cost per LYG could range between £6,000 - £8,500 depending on the trial data used. 
However, this would only be possible realistically if the dosage of paclitaxel were to 
increase. 
 
The following table explores the cost per LYG ratio using the ECOCIT data as its basis. The 
analysis considers three scenarios around possible variations in terms of hospitalisation 
rates and dosages of paclitaxel. 
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Table 21 Potential Change in Cost per Life Year Gained  
 Paclitaxel at 
135 mg/m
2 
2 days’  
in-patient stay  
(24 hr infusion) 
Paclitaxel at 
175 mg/m
2 
1 day  
in-patient stay 
(3 hr infusion) 
Paclitaxel at 
200 mg/m
2 
1 day  
in-patient stay 
(3 hr infusion) 
Cost of TP £10,427 £11,045 £12,365 
Marginal Cost £8,368 £8,980 £10,306 
LYG 0.83 0.83 0.83 
Cost per LYG £10,081 £10,827 £12,417 
 
As a high proportion of the TP treated patients experienced a dosage increase during the 
period, consideration has been given to the cost per LYG incorporating this potential 
increase in drug cost. Calculating 100% of the paclitaxel costs at a 200 mg/m
2
 dosage, the 
cost of TP therapy is estimated at £10-14,000 based on six treatment courses. It is 
important to note that there is still no clinical evidence to indicate that 200 mg/m
2
 is any 
better than 175 mg/m
2
. 
 
Overall, the cost-effectiveness analysis remains steady irrespective of possible movement in 
costs which variations in treatment regimens could bring. 
 
3.3  Secondary Analysis 
 
Confidence intervals on median survival 
As a secondary analysis a further look has been taken at the survival event data presented 
in the ASCO abstract 1998. Using the methodology detailed by Altman,
22
 it is possible to 
make approximations to the confidence range around the ratio of median survival times (see 
Chapter 2). 
 
This analysis gives the range 1.11 to 1.76 years as the 95% confidence interval for the 
difference between the median survival times. A more accurate estimate would be possible 
using the actual trial data, although this calculation does at least allow the magnitude of the 
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range to be considered. Using this approximated confidence range, the difference between 
treatment could range from three months (0.3 LYG) to 19 months (1.6 LYG). On this basis 
the cost per LYG could vary between £5,255 - £28,000 due to a sampling error in estimating 
the median survival times.  
 
An interesting analysis would be to consider further the variance of median survival from the 
combined trial data. This would potentially narrow the width of the confidence interval, as 
was seen with the pooled relative risk, or hazard ratio.  
 
Area Under the Curve Analysis 
Whilst the comparison of median survival statistics is a common approach in comparing trial 
arms, it is still very much a single point estimate of any real difference between the 
treatment effects. It may be that at other times the relative outcome differences vary. In 
cases where there are longer-term benefits to a treatment, as in a potential plateau state, or 
where early mortalities are experienced with more aggressive treatments, as in high dose 
therapy, median point estimates may mask the true impact of a treatment 
 
One approach to counter this potential bias is to consider the actual area under the curve 
(AUC) for the two separate trial arms. A comparison of these two AUC estimates suggests 
an alternative estimate of benefit difference.  
 
The following graph shows an approximation of the survival curve for the TP and CP arms of 
the ECOCIT. The 6-monthly data points have been taken from the presented slides and 
therefore, represent estimates only. 
 
Figure 1 Area Under the Curve Estimate of Benefit 
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Based on these data, the AUC estimates for the TP and CP trial arms are 28 and 24 months 
respectively. Therefore, the implied marginal benefit of TP is four months, representing 0.33 
LYG. However, in this case the patient numbers at the end of the trial remain low and long-
term cure is not achieved.  For this reason our main analysis is based upon median point 
statistics. 
 
3.4  Published Cost-effectiveness Analysis 
 
Since the publication of the original Trent WGAP Report there have been a number of 
subsequently published cost-analyses, focusing specifically on the role of TP as a first line 
therapy for AOC. 
 
A follow-up literature search has been conducted to identify studies dealing specifically with 
the cost-effectiveness of paclitaxel.  Search terms included ‘paclitaxel’, ‘taxol’, ‘ovarian 
neoplasms’, ‘ovarian cancer’, ‘meta analysis’, ‘health care planning’, ‘economic aspects’, 
‘costs and cost analysis’, ‘economics’ and ‘practice guidelines’. The search was conducted 
over the period 1994-1998.  
 
As a result, eight key economic analyses were identified, including the original Trent based 
UK study, covering a variety of different health care settings including the UK, USA, Italy 
and Canada. Whilst all the studies necessarily have the same evidence-base, the GOG-111 
trial, they use a range of different economic analyses and modelling techniques,  applied in 
a variety of different health care contexts. 
 
The majority of the studies used LYG as the currency of clinical benefit, although two 
studies quote data using progression-free years, one of which was the Trent WGAP report. 
The use of progression-free years is an attempt to account for benefits in terms of years 
spent in relative good health. However, it is entirely possible for patients to lead a 
reasonable quality of life even in early disease progression. Therefore, LYG is still a good 
measure of benefit. Two studies also make adjustments to clinical benefit to account for 
quality of life, in terms of quality adjusted life years (QALY)s.  
 
Some of the studies include the costs of first-line therapy only, whilst others base their cost 
calculations on a more life-time treatment basis (i.e. including the cost of subsequent 
phases of salvage therapy).  
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All the studies point clearly towards the relative cost-effectiveness of TP. Costs have been 
included on a mix of first-line only and  lifetime costs basis. 
 
The following graph compares the published cost-effectiveness ratios of these studies. 
 
Figure 2 Comparison of Published Cost-Analyses 
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Whilst each study is set within the context of its own health care system, it is interesting to 
see that, in general, the figures tend to lie within a very similar range of cost-effectiveness. 
Again, this is not surprising given the limitation of the trial data. However, the studies cost 
treatment on very different bases, some using bottom-up costings from retrospective patient 
studies whilst others make general modelled assumptions around average cost figures. 
 
The following table provides a summary view of the basic approach and conclusions of 
these reports and further highlights the type of sensitivity analysis performed. 
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Table 22 Economic Modelling to Determine the Cost-effectiveness of Paclitaxel in the Treatment of Ovarian Cancer 
Authors Country Treatments 
Compared 
Method  Benefit/CE 
Measures 
Sensitivity Analysis Authors Conclusions 
Beard  
et al.
10
 
UK  
(1997) 
1st-line  therapy 
TP vs 
Carboplatin. 
Survival analysis based on published 
trial median statistics, with 
supporting survival curve analysis. 
 
Area under survival curve using 
Weibull curve fitted to survival data. 
 cost per LYG 
 cost per 
progression-
free year  
gained 
(PFYG) 
 
 hospital costs 
 adverse effects, costs  
 cost of paclitaxel 
 clinical benefits 
 LYG : 1.17 & PFYG : 0.42 
 cost per LYG : £7,200 
 cost per PFYG : £20,084 
 LYG : 0.53 (based on AUC 
estimates of benefit) 
 cost per LYG : £15,788 (based 
on AUC estimates of benefit) 
 marginal cost of £8,000 per 
patient 
 marginal cost of £260,000 for a 
typical UK health authority 
 
Best & 
Anthony
27
 
UK  
(1996) 
1st-line  therapy 
TP vs  
Carboplatin vs  
CAP vs 
no treatment. 
TP benefits taken from GOG111 
median survival times. 
CAP and CARB benefits derived by 
combining several small RCTs.  
 QALYs  survival benefits of no 
treatment 
 dosage of Carboplatin 
 1.1 QALYs per patient on TP 
c.f. Carboplatin 
 cost per QALY = £5,297 c.f. 
Carboplatin 
 extra 110 QALYs per 100 
patients when c.f. Carboplatin 
 marginal cost of  £580,000 per 
100 patients c.f. Carboplatin 
 
Ortega
28
 CANADA 
(1997) 
1st-line  therapy 
TP vs CP 
also included 
variations in 
2nd and 3rd line 
therapies. 
Cost utility analysis based on a 
decision-tree model. 
Localised costings combined with 
patient record tracking of resource 
usage. Treatment preference study 
to identify utility of health states. 
Quality adjusted  
PFYG 
 variety of 2nd and 3rd 
line therapies 
 healthy volunteers 
utility scores 
 95% CI of benefits 
and costs 
 cost per quality adjusted PFYG 
lay between £5,000 
(Can$11,000) to £10,000 
(Can$24,000) 
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Authors Country Treatments 
Compared 
Method  Benefit/CE 
Measures 
Sensitivity Analysis Authors Conclusions 
Covens  
et al.
29
 
CANADA 
(1996) 
1st-line  therapy 
TP vs 
CP. 
Also included 
costs of 2nd 
and 3rd line 
therapy 
Linear modelling based cost-benefit 
analysis designed to combine costs 
and expected benefits. 
Based on four stages of patient 
treatment defined as: 
 surgery/chemotherapy/relapse/ 
terminal care. 
 time/proportion in stages 
determined from retrospective 
chart analysis.  
 assume a 50% increase in 
survival for paclitaxel. 
  
 average life 
time cost per 
patient 
 cost per LYG 
 drug costs 
 longer TP infusion 
 survival benefits  
(25%,50% ,75%) 
 average life time cost per 
patient :  
 TP at £20,800 
(Can$50,054) 
 CP at £15,400 
(Can$36,837)  
 cost per LYG cost for TP was 
£8,500 (Can$20,355) 
 sensitivity analysis indicates a 
cost per LYG range of £6,400 - 
£11,200 
 
Elit 
et al.
30
 
CANADA 
(1997) 
1st-line  therapy 
TP vs 
CP 
Standard cost-effectiveness study 
using mean data derived directly 
from the GOG-111 survival  curves.   
 cost per LYG  drug costs 
 benefits 
 cost per LYG for TP was 
£7,300 (Can$17,500) 
 
 
Messori 
et al.
31
 
ITALY 
(1996) 
1st-line  therapy 
TP vs 
CP  
 
Incremental cost-effectiveness 
analysis. 
Survival curve fitting of trial data 
using weighted least squares 
procedure, best fit Gompertz curve. 
Extrapolation beyond trial data to life 
benefits. 
 LYG   
 cost per LYG 
 drug costs 
 hospitalisation costs 
 benefits limited to trial 
period 
 46 LYG per 100 patients.  
 extra cost of £563,500 
(US$901,723) per 100 patients     
 cost per LYG for TP was: 
£12,300 (US$19,603) 
 sensitivity analysis presents a 
cost per LYG range of 
£10,000-£14,250 (US$15,960-
$22,793). 
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Authors Country Treatments 
Compared 
Method  Benefit/CE 
Measures 
Sensitivity Analysis Authors Conclusions 
McGuire  
et al.
32
 
USA 
(1997) 
1st-line  therapy 
TP vs 
CP 
Cost-effectiveness study based on 
the GOG-111 trial. 
Treatment cost data applied to 
resource utilisation data. 
Median survival data and equivalent 
mean survival data used to 
determine benefits. 
Estimates of cumulative proportion 
surviving in the trial were based on 
Kaplan-Meier procedures. 
No account taken of patient utility 
and QoL. 
 LYG   
 cost per LYG 
 Monte Carlo analysis 
of clinical benefits 
 Use of different 
estimates of benefits 
based on median 
survival and mean 
survival data 
 cost per LYG: 
 mean survival data to 
present time:  £6,500 
(US$10,454) 
 mean survival data to 
end of trial: £12,400 
(US$19,820) 
 median trial survival 
data: £5,800 
(US$9,323) 
 expected distribution from 
multivariate Monte Carlo 
analysis: £12,400±£680 
(US$19,868±US$1087) per 
LYG. 
Berger K, 
Szucs T
33  
(abstract 
only) 
 
 
 
 
 
Europe 
(1997) 
1st-line  therapy 
TP vs 
CP 
Face-face interviews with 
oncologists. 
Costs built from local telephone 
interviews with health providers. 
Calculations made for 6 individual 
European countries (D,E,F,I,NL,UK). 
Benefits based on GOG-111. 
Declining exponential approximation 
of life expectancy (DEALE) used in 
calculating LYS. 
 LYG   
 cost per LYG 
 Sensitivity analysis 
conducted but not 
detailed in abstract 
 Range of LYG estimated at: 
1.27-1.3 LYG 
 Marginal treatment cost for UK: 
£5,062  (US$ 8,100) 
 Cost per LYG of UK :  £4,000 
(US$6,400) 
 Improved ratio using a 3 hour 
infusion (reduced 
hospitalisation costs) 
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4.  DISCUSSION AND CONCLUSIONS 
 
The presentation of the results from the ECOCIT provides further support to the clinical 
efficacy of TP in the first line treatment of AOC. The  trial data indicate: 
 a confirmation of the magnitude of benefits, in terms of both overall survival and 
progression-free survival, as reported in the GOG-111 trial; 
 a similar range of side-effect profiles to those observed in the GOG-111 trial (more data 
may be needed to confirm this comparison); 
 indications of significant benefit to a wider patient group, including stage IIB and IIC 
patients; 
 confirmation of the efficacy of shorter infusions of paclitaxel (3 hour intravenous 
infusion); 
 the potential to deliver therapy on an out-patient basis. 
 
Importantly, the survival and progression-free advantages still remained significant when 
using an intention-to-treat basis, with cross-over allowed for salvage therapy after disease 
progression. It is likely that full publication of the trial results will provide even more detail 
confirming these results. 
 
The next major trial data to take into account will be the interim results and final publication 
of mature data from the ICON 3 trial. This will represent the first major trial of paclitaxel to 
make a direct comparison to UK conventional therapy., results are not due for another two 
years. However 
 
All published economic studies to date have been based on the GOG-111 RCT. Although 
each economic analysis approaches the problems of cost-effectiveness modelling from a  
slightly different perspective and using a different methodology, they appear to arrive at the 
same conclusion, namely, that TP as a first line therapy provides cost-effectiveness ratios 
comparable to other interventions currently supported by the NHS.  
 
Many unanswered questions remain regarding the treatment of AOC with paclitaxel, such 
as, the place of using more cycles of treatment. The effects of intra-peritoneal delivery of 
chemotherapy, high dose consolidation therapy and IDS are also not known. Research 
currently being undertaken in the treatment of AOC using paclitaxel will clarify many of the 
unanswered questions with regard to clinical and cost-effectiveness.   
  36 
 
Whilst the economics of paclitaxel remain relatively favourable on a patient-by-patient basis, 
the overall budgetary impact remains unquestionably substantial. Over the next few years 
there is likely to be much more debate and consideration of the relative merits of other new 
treatments for ovarian and other gynaecological cancers, with pressure to target resources 
effectively. 
 
The key messages of the ECOCIT appear positive, confirming the clinical benefits achieved 
in the original GOG-111 trial. The results have been presented and debated in the context of 
local and national gynaecology group meetings, with positive clinical statements produced in 
the form of a recent clinical consensus document and a JCCO statement. Clinical opinion 
suggests that paclitaxel in combination with cisplatin or (probably) carboplatin would be the 
treatment of choice for the majority of women with ovarian cancer.  
 
The JCCO statement has been endorsed by the NHS SMAC. Final publication and 
dissemination of the ECOCIT results is due and is expected to re-enforce this clinical view. 
The eventual completion and publication of the ICON 3 results, in around two years’ time, 
will allow these clinical views to be revisited. 
 
Pre-publication note (10/02/99) 
 
Since the original considerations of the Trent DEC, there has been further publication of 
final overall survival data from the ICON 2 trial.
28
 ICON 2 makes a direct comparison 
between single agent carboplatin and platinum combination CAP and, importantly, confirms 
equity in terms of overall survival. However, the median survival (33mths), is notably much 
higher than either the control arms of the two international paclitaxel comparison studies 
(CP 24-25mths) or the Wessex report (CARB 20mths / CAP 24mths).
9,11,27
 Although ICON 2 
does not present comparative data with paclitaxel, if such results were repeated in a direct 
carboplatin/CAP/paclitaxel study, they may imply potentially smaller marginal survival 
benefits for paclitaxel over conventional therapy. 
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APPENDIX   POOLED ANALYSIS OF TRIAL DATA 
 
The following presents a step-by-step pooled analysis of the relative risks suggested by the 
data from the two trials. The methodology used is based on the general variance-based 
method using confidence intervals. 
Study 1 = GOG-111 trial 
Study 2 = ECOCIT  
RRi = relative risk of the i
th
 trial 
RRp = relative risk of the pooled data 
Weighti = weight assigned to the i
th
 trial 
 
Log-transformation of RR   
Study 1 ln(RR1) = ln(0.6) = -0.5118 
Study 2 ln(RR2) = ln(0.71) = -0.3425 
 
Estimated Variance 
Vari
RRi RRil





ln( / )
.196
2
 
Study 1 Var1 = [ln(RR1/RR1L)/1.96]^2 = [ln(0.6/0.5)/1.96]^2 = 0.0087 
Study 2 Var2 = [ln(RR2/RR1L)/1.96]^2 = [ln(0.6/0.5)/1.96]^2 = 0.0126 
 
Estimated Weights 
Weighti
Vari

1
 
Study 1   Weight1 = 1 / Var1 = 1/0.0087 = 115.5676 
Study 2   Weight2 = 1 /Var2 = 1/0.0126 = 79.6406 
Sum of Weights = Weight1 + Weight2 = 115.5676 + 79.6406 = 195.2082 
 
Products 
Study 1  Product1 = Weight1 * ln(RR1) = 115.5676 X -0.5118 = -59.0349 
Study 2  Product2 = Weight2 * ln(RR2) = 79.6406 X -0.3425 = -27.2761 
Sum of the Products = Product1 + Product2 = -59.0349 -27.2761 = -86.3110 
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Estimate of Pooled Relative Risk 
RRp e
Sum of Pducts
Sum of Weights







~ ~
~ ~
 
RRp = e^(Sum of Products/Sum of Weights) = e^(-86.3110/195.2082) = e^(-0.4421) = 0.64 
 
Estimate of 95% C.I. 
  
CI e
RR X iance

ln( ) . var1 96
 
Upper bound = e^(ln(RRp) +(1.96 X SQRT(1/195.2082))  = e^(-0.4421 + 0.1403) = 0.74 
Lower bound = e^(ln(RRp) -(1.96 X SQRT(1/195.2082))  = e^(-0.4421 - 0.1403) = 0.56 
 
Estimate of Significance 
 
It is possible to construct a test of significance for the RRp by standardising it to a standard 
normal distribution. 
 
RRp/SQRT(1/variance) = 0.64/SQRT(1/195.2082) = 8.9419 
 
Using the standard normal distribution p(Z<8.9419) <= 0.0000001 
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